ANTIGEN

Novel mRNA-lipid nanoparticle vaccine encoding four mpox virus surface proteins generates robust immune responses against orthopoxviruses

by

In a recent study posted to the bioRxiv* preprint server, researchers described a messenger ribonucleic acid (mRNA)-lipid nanoparticle mpox vaccine encoding four conserved mpox virus surface proteins which induced mpox virus-specific immunity and elicited heterologous protection when challenged with lethal vaccinia virus. Study: A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives … Read more

SARS-CoV-2 and human cold coronavirus OC43 inhibit stress granule formation through Nsp15 protein

by

In a recent study published in the journal PLOS pathogensresearchers investigated the mechanisms through which the human common cold Betacoronavirus OC43 (HCoV-OC43) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit the formation of stress granules. Study: Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation. Image Credit: MIA Studio/Shutterstock Background Stress … Read more

Study demonstrates robust antibody response elicited by trivalent protein subunit vaccine against SARS-CoV-2

by

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that a trivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) improved the breadth of humoral immune responses in mice. Study: Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice. Image Credit: Corona Borealis Studio/Shutterstock Background SARS-CoV-2 vaccines … Read more

Exploring a variant-adapted SARS-CoV-2 recombinant protein vaccine

by

In a recent study posted to the medRxiv* preprint server, researchers assessed the immunogenicity of a variant-adapted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine boosted with an AS03 adjuvant. Study: Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines. … Read more

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

by

In a recent study posted to the bioRxiv* server, researchers mutated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein’s trimeric structure to design a novel prefusion S antigen, S2D14. Study: Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved Immunogenicity. Image Credit: creativeneko/Shutterstock Background … Read more

Chitin-immobilized nanobodies for SARS-CoV-2 detection

by

In a recent study posted to bioRxiv*, researchers demonstrated a novel strategy to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using chitin-immobilized nanobodies. Study: Efficient SARS-CoV-2 detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis. Image Credit: CROCOTHERY/Shutterstock Background Shark and Camelidae-derived nanobodies are emerging alternatives to traditional antibodies. Nanobodies bind to ligands at the … Read more

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

by

The findings of a new study posted to the bioRxiv* preprint server showed that the intranasal SpyCage vaccine platform can be protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens. Study: Intranasal virus-particle mimicking vaccine … Read more

Dyadic Receives Regulatory Approval to Initiate Phase 1

by

JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today … Read more